1. Report Overview
1.1 Global Acute Myeloid Leukaemia Market Overview
1.2 Market Definition & Scope
1.3 Overview of Findings
1.4 Structure of the Report1.5 Key Questions Answered by This Analytical Report
1.6 How This Report Delivers
1.7 Who is This Report For?
1.8 Methodology
1.8.1 Primary Research
1.8.2 Secondary Research
1.8.3 Market Evaluation & Forecasting Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Acute Myeloid Leukaemia
2.1 Market definition and scope
2.2 Myeloid Leukaemia: An Overview
2.2.1 Phases of treatment
2.2.2 Medication Overview
2.3 The Need of Acute Myeloid Therapeutics
3. Acute Myeloid Leukaemia Market: World Market 2018-2028
3.1 The World Acute Myeloid Leukaemia Market Overview and Segmentation, 2017
3.2 World Acute Myeloid Leukaemia Market: Sales Forecast 2017-2028
3.3 How Will Segments Market Shares Change to 2028?
4. Global Acute Myeloid Leukaemia Market by Treatment Type 2018-2028
4.1 Market Size and Forecast 2017-2028
4.2 Chemotherapy
4.2.1 Chemotherapy Market Size and Forecast 2017-2028
4.2.2 Cytarabine Market Size 2017-2028
4.2.3 Daunorubicin Market Size 2017-2028
4.2.4 Other Chemotherapy Products Market Size 2017-2028
4.3 Targeted Therapy
4.3.1 Targeted Therapy Market Size and Forecast 2017-2028
4.3.2 Midostaurin Market Size and Forecasts 2017-2028
4.3.3 Enasidenib Market Size and Forecasts 2017-2028
4.3.4 Other Targeted Therapy Products Market Forecasts 2017-2028
5. Global Acute Myeloid Leukaemia Market by Region 2018-2028
5.1 Global Acute Myeloid Leukaemia Market by Region: Revenue Forecast, 2018-2028
5.2 North America AML Market Forecast 2017-2028
5.2.1 North America Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.2.1.1 US Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.2.1.2 Canada Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.2.1.3 Mexico Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3 Europe Acute Myeloid Leukaemia Market Forecast 2017-2028
5.3.1 Europe Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.3.1.1 Germany Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.2 France Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.3 United Kingdom Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.4 Italy Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.5 Spain Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.6 Russia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.3.1.7 Rest of Europe Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4 Asia-Pacific Acute Myeloid Market Forecasts 2018-2028
5.4.1 Asia-Pacific Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.4.1.1 Japan Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.1.2 China Acute Myeloid Leukaemia Market, Revenue Forecast, 2018-2028
5.4.1.3 Australia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.1.4 South Korea Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.1.5 India Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.4.2 Rest of Asia-Pacific Acute myeloid leukaemia Market, Revenue Forecast, 2018-2028
5.5 LAMEA Acute Myeloid Market Forecasts 2018-2028
5.5.1 LAMEA Acute Myeloid Leukaemia Market by Country: Revenue Forecast, 2018-2028
5.5.1.1 Brazil Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.5.1.2 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.5.1.3 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
5.5.1.4 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue Forecast, 2018-2028
6. Leading Companies in Acute Myeloid Leukaemia Market
6.1 Daiichi Sankyo
6.1.1 Company Overview
6.1.2 Financial Highlights
6.1.3 Recent Strategic Developments
6.2 Celgene Corporation
6.2.1 Company Overview
6.2.2 Operating Segments
6.2.3 Financial Highlights
6.2.4 Recent Strategic Developments
6.3 TEVA Pharmaceutical Industries Limited
6.3.1 Company Overview
6.3.2 Operating Segments
6.3.3 Financial Highlights
6.3.4 Recent Strategic Developments
6.4 Eisai Co., Ltd.
6.4.1 Company Overview
6.4.2 Operating Segments
6.4.3 Financial Highlights
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Operating Segments
6.5.3 Financial Highlights
6.5.4 Recent Strategic Developments
6.6 GlaxoSmithKline plc
6.6.1 Company Overview
6.6.2 Operating Segments
6.6.3 Financial Highlights
6.7 Sunesis Pharmaceuticals, Inc.
6.7.1 Company Overview
6.7.2 Operating Segments
6.7.3 Financial Highlights
6.8 Clavis Pharma ASA
6.8.1 Company Overview
6.9 F. Hoffmann-La Roche Ltd.
6.9.1 Company Overview
6.9.2 Operating Segments
6.9.3 Financial Highlights
6.9.4 Recent Strategic Developments
6.10 Bristol-Myers Squibb Company
6.10.1 Company Overview
6.10.2 Operating Segments
6.10.3 Financial Highlights
7. Acute Myeloid Leukaemia Market: Qualitative Analysis
7.1 Market Dynamics
7.1.1 Drivers
7.1.1.1 Rise in Cases of Chronic Diseases
7.1.1.2 Research for Innovative Therapeutics
7.1.1.3 Growth in Aging Population Base Worldwide
7.1.2 Restraints
7.1.2.1 Adverse Effects of the Treatment
7.1.3 Opportunities
7.1.3.1 Unmet oncological therapeutics demand.
7.1.3.2 Untapped opportunities in the developing nations
8. Pipeline and clinical trials analysis
8.1 Pipeline analysis
8.1.1 Vosaroxin (Sunesis Pharmaceuticals)
8.1.2 CPX-351 (Celator Pharmaceuticals, Inc.)
8.1.3 Sapacitabine (Cyclacel)
8.1.4 SGI-110 (Astex)
8.2 Small-Molecule Targeted Therapies
8.2.1 Volasertib (Boehringer Ingelheim)
8.3 Isocitrate Dehydrogenase Inhibitors
8.3.1 ABT-199s (AbbVie, Roche)
8.3.2 FLT3 Inhibitors
8.3.3 Sorafenib (Bayer, Onyx Pharmaceuticals)
8.3.4 Midostaurin (Novartis)
8.3.5 Quizartinib (Daiichi Sankyo)
8.4 Monoclonal Antibodies
8.4.1 SGN-33A (Seattle Genetics)
8.4.2 AMG-330 (Amgen)
8.5 Clinical trials
9. Conclusion
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report evaluation form
List of Tables
Table 4.1 Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.2 Chemotherapy Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.3 Cytarabine Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.4 Daunorubicin Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.5 Other Chemotherapy Products Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.6 Targeted Therapy Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.7 Midostaurin Market Forecasts: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.8 Enasidenib Market Forecast: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 4.9 Other Targeted Therapy Products Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.1 Global Acute Myeloid Leukaemia Market: Revenue ($m), Revenue Share (%) by Region, 2017, 2023, 2028
Table 5.2 Global Acute Myeloid Leukaemia Market by Leading National Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.3 US Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.4 Canada Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.5 Mexico Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.6 Europe Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.7 Germany Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.8 France Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.9 United Kingdom Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.10 Italy Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.11 Spain Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.12 Russia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.13 Rest for Europe Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.14 Asia-Pacific Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.15 Japan Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.16 China Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.17 Australia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.18 South Korea Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.19 India Acute myeloid leukaemia Market, Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.20 Rest of Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.21 LAMEA Acute myeloid leukaemia Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.22 Brazil Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.23 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.24 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 5.25 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
Table 6.1 Daiichi Sankyo: Revenue ($m), R&D ($m), 2015-2017
Table 6.2 Daiichi Sankyo Recent Developments
Table 6.3 Celgene: Revenue ($m), R&D ($m), 2015-2017
Table 6.4 Celgene Recent Developments
Table 6.5 TEVA Operating Segments
Table 6.6 TEVA: Revenue ($m), R&D ($m), 2015-2017
Table 6.7 TEVA Recent Developments
Table 6.8 Eisai Operating Segments
Table 6.9 Eisai Revenue ($m), R&D ($m), 2015-2017
Table 6.10 Novartis Operating Segments
Table 6.11 Novartis: Revenue ($m), R&D ($m), 2015-2017
Table 6.12 Novartis Recent Developments
Table 6.13 GSK Operating Segments
Table 6.14 GSK: Revenue ($m), R&D ($m), 2015-2017
Table 6.15 Sunesis: Revenue ($m), R&D ($m), 2015-2017
Table 6.16 Roche Operating Segments
Table 6.17 Roche: Revenue ($m), R&D ($m), 2015-2017
Table 6.18 Roche Recent Developments
Table 6.19 Bristol-Myers: Revenue ($m), 2015-2017
Table 8.1 AML Drugs in the Pipeline: Agent, MOA, Clinical Trial Code
Table 8.2 Completed Clinical Trials for AML
Table 8.3 List of Recruiting Clinical Trials for AML
Table 9.1: Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), 2017, 2023, 2028
List of Figures
Figure 3.1 Global Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 3.2 Global Acute Myeloid Leukaemia Market Revenue: Market Shares (%), 2017-2028
Figure 4.1 Chemotherapy Market Forecasts: Revenue ($m), 2017-2028
Figure 4.2 Cytarabine Market Forecasts: Revenue ($m), 2017-2028
Figure 4.3 Daunorubicin Market Forecasts: Revenue ($m), 2017-2028
Figure 4.4 Other Chemotherapy Products Market: Revenue ($m), 2017-2028
Figure 4.5 Targeted Therapy Market Forecasts: Revenue ($m), 2017-2028
Figure 4.6 Midostaurin Market Forecasts: Revenue ($m), 2017-2028
Figure 4.7 Enasidenib Market Forecast: Revenue ($m), 2017-2028
Figure 4.8 Other Targeted Therapy Products Market: Revenue ($m), 2017-2028
Figure 5.1 Global Acute Myeloid Leukaemia Market: Revenue ($m) by Leading Nationals, 2017-2028
Figure 5.2 US Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.3 Canada Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.4 Mexico Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.5 Europe Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.6 Germany Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.7 France Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.8 United Kingdom Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.9 Italy Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.10 Spain Acute myeloid leukaemia Market, Revenue ($m), 2017-2028
Figure 5.11 Russia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.12 Rest of Europe Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.13 Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.14 Japan Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.15 China Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.16 Australia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.17: South Korea Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.18 India Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.19 Rest of Asia-Pacific Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.20 LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.21 Brazil Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.22 Saudi Arabia Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.23 Republic of South Africa Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 5.24 Rest of LAMEA Acute Myeloid Leukaemia Market: Revenue ($m), 2017-2028
Figure 9.1: Global Acute Myeloid Leukaemia Market by Treatment Type: Revenue ($m), 2017, 2023, 2028
